The FDA Wednesday issued its fiscal 2020 rates for drug compounders that register with the agency as outsourcing facilities.

Outsourcing facilities whose total global annual sales totaled over $1 million by April 1 of FY 2019 are not seen as small businesses by the FDA and must pay the $18,288 non-small business establishment fee.

Those that made $1 million or less by that date qualify as small businesses and may pay the $5,599 establishment fee. Regardless of their size, all outsourcing facilities must pay the $16,798 reinspection fee.